Cytokinetics (CYTK) Preferred Dividend Payments (2011 - 2012)
Cytokinetics (CYTK) posted quarterly Preferred Dividend Payments of $1.3 million for Q2 2012, down 54.25% year-over-year from $2.9 million in Q3 2011, and down 54.25% quarter-over-quarter from $2.9 million in Q2 2011.
Powered by 
Analysis
Cytokinetics (CYTK) Preferred Dividend Payments (2011 - 2012) Analysis & Trends
Cytokinetics (CYTK) has reported Preferred Dividend Payments for 2 consecutive years, with $1.3 million the latest figure, recorded in Q2 2012.
- In Q2 2012, Preferred Dividend Payments fell 54.25% year-over-year to $1.3 million; the TTM figure through Dec 2012 stood at $1.3 million (changed N/A YoY), while the FY2012 annual figure was $1.3 million, down 54.25% from the prior year.
- Preferred Dividend Payments fell to $1.3 million in Q2 2012 per CYTK's latest filing, from $2.9 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.9 million in Q2 2011 and bottomed at $1.3 million in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 9.60 Bn | 8.43 Bn | 25.89 Mn | - |